N4 Pharma Plc
N4P.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.06 | 0.02 | 0.08 |
| FCF Yield | -20.55% | 0.00% | -32.23% | -26.98% |
| EV / EBITDA | -0.92 | -1.59 | -0.02 | -1.44 |
| Quality | ||||
| ROIC | -28.38% | -88.58% | -38.31% | -52.92% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.89 | 0.86 | 0.93 | 0.97 |
| Growth | ||||
| Revenue 3-Year CAGR | 234,580.42% | 209,703.29% | 180,177.35% | 124,897.33% |
| Free Cash Flow Growth | 0.00% | 0.00% | 32.68% | 7.63% |
| Safety | ||||
| Net Debt / EBITDA | 3.67 | 0.86 | 2.45 | 1.32 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 2,880.80 | 3,590.06 | 1,590.35 | 8,130.51 |